血γ干扰素诱导蛋白10检测对判断肺结核患者治疗效果的价值

doi:10.3969/j.issn.1000-6621.2019.02.011

摘要/Abstract

摘要：

目的探讨活动性肺结核患者治疗前后血清γ干扰素诱导蛋白10(IP-10)和全血可溶性γ干扰素释放试验(QFT-GIT)抗原应答的IP-10变化情况。方法搜集2017年1—3月河北省胸科医院收治的经过6~9个月规律抗结核药物治疗后好转的活动性肺结核患者161例。根据治疗前痰涂片抗酸染色结果,分为菌阳肺结核患者(82例)和菌阴肺结核患者(79例)。其中,菌阳肺结核患者根据抗结核药物治疗2个月末痰涂片抗酸染色结果,分为治疗2个月痰菌阴转患者(A组;31例)和治疗2个月痰菌未阴转患者(B组;51例);将菌阴肺结核患者作为C组(79例)。测定三组患者抗结核药物治疗2周内、治疗2个月末、疗程结束后(治疗6~9个月)血清IP-10水平及QFT-GIT抗原应答的IP-10水平,并进行比较。结果 A、B、C三组患者治疗2周内、治疗2个月末和疗程结束后的血清IP-10水平分别为(0.16±0.03)μg/L、(0.13±0.03)μg/L、(0.09±0.02)μg/L,(0.16±0.03)μg/L、(0.15±0.03)μg/L、(0.09±0.02)μg/L和(0.16±0.03)μg/L、(0.13±0.03)μg/L、(0.09±0.02)μg/L;QFT-GIT抗原应答的IP-10水平分别为(21.60±3.07)μg/L、(19.94±3.05)μg/L、(11.01±2.16)μg/L,(23.52±3.10)μg/L、(20.50±4.60)μg/L、(12.08±3.57)μg/L和(19.67±3.32)μg/L、(13.43±3.16)μg/L、(8.72±1.08)μg/L。A、B、C组3个治疗时间点血清IP-10和QFT-GIT抗原应答的IP-10水平差异均有统计学意义(F值分别为72.84、111.92、107.52和75.01、118.09、138.98,P值均为0.000)。三组患者疗程结束后血清IP-10、QFT-GIT抗原应答的IP-10水平均低于治疗2周内,差异均有统计学意义(A组q值分别为71.42和138.42;B组q值分别为74.68和150.29;C组q值分别为68.76和129.83,P值均为0.000)。结论血清IP-10及QFT-GIT抗原应答的IP-10水平均可监测治疗效果,可作为监测活动性肺结核治疗效果的潜在生物标志物。

关键词: 结核,肺, 趋化因子,CXC, 治疗结果, 判别分析

Abstract:

Objective To investigate the changes of serum interferon-gamma-inducible protein 10 (IP-10) and IP-10 response against tuberculosis specific antigens in QuantiFERON Gold In-Tube (QFT-GIT) assay in patients with active pulmonary tuberculosis before and after treatment. Methods A total of 161 cases of active pulmonary tuberculosis who were improved after 6-9 months of regular antituberculosis treatment in Hebei Provincial Chest Hospital during January 2017 to March 2017 were enrolled in this study. Patients were divided into anti-acid staining (+) group (82 cases) and anti-acid staining (-) group (79 cases) according to the results of sputum smear anti-acid staining before treatment. Anti-acid staining (+) group was further divided into group A (anti-acid staining change (-) after 2 months of treatment, 31 cases) and group B (anti-acid staining still (+) after 2 months of treatment, 51 cases). Anti-acid staining (-) group was defined as the group C (79 cases). The levels of serum IP-10 and IP-10 response to antigen in QFT-GIT assay were measured and compared in all groups within 2 weeks, at the end of 2 months and after 6-9 months of treatment. Results The levels of serum IP-10 within 2 weeks, at the end of 2 months and after 6-9 months of treatment were (0.16±0.03)μg/L, (0.13±0.03)μg/L and (0.09±0.02)μg/L in group A, (0.16±0.03)μg/L, (0.15±0.03)μg/L and (0.09±0.02)μg/L in group B, and (0.16±0.03)μg/L, (0.13±0.03)μg/L and (0.09±0.02)μg/L in group C, respectively. The levels of IP-10 response to antigen in QFT-GIT assay within 2 weeks, at the end of 2 months and after 6-9 months of treatment were (21.60±3.07)μg/L, (19.94±3.05)μg/L and (11.01±2.16)μg/L in group A, (23.52±3.10)μg/L, (20.50±4.60)μg/L and (12.08±3.57)μg/L in group B, and (19.67±3.32)μg/L, (13.43±3.16)μg/L and (8.72±1.08)μg/L in group C, respectively. The differences in the levels of serum IP-10 and IP-10 response to antigen in QFT-GIT assay among the three treatment time points in group A, B and C were all statistically significant (F values were 72.84, 111.92, 107.52 and 75.01, 118.09, 138.98, respectively; Ps=0.000). The levels of serum IP-10 and IP-10 response to antigen in QFT-GIT assay after the course of treatment were lower than those within 2 weeks of treatment, and the differences were statistically significant (group A: q values were 71.42 and 138.42; group B: q values were 74.68 and 150.29; group C: q values were 68.76 and 129.83; Ps=0.000). Conclusion Serum IP-10 and IP-10 response to antigen in QFT-GIT assay can be used as potential biomarkers for monitoring the treatment effect of patients with active pulmonary tuberculosis.

Key words: Tuberculosis,pulmonary, Chemokines,CXC, Treatment outcome, Discriminant analysis

魏兰,秦学博,段小亮,李辉,李玉琢,贾新转,张磊. 血γ干扰素诱导蛋白10检测对判断肺结核患者治疗效果的价值[J]. 中国防痨杂志, 2019, 41(2): 181-185. doi: 10.3969/j.issn.1000-6621.2019.02.011

Lan WEI,Xue-bo QIN,Xiao-liang DUAN,Hui LI,Yu-zhuo LI,Xin-zhuan JIA,Lei ZHANG. The value of blood interferon-gamma-inducible protein 10 level in assessing the treatment efficacy of pulmonary tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2019, 41(2): 181-185. doi: 10.3969/j.issn.1000-6621.2019.02.011

图/表 2

表1

三组患者年龄、性别和BMI的比较

组别	例数	年龄 (岁, $x ˉ$ ±s)	性别 [例(构成比,%)]		BMI (kg/m²)
组别	例数	年龄 (岁, $x ˉ$ ±s)	男	女	BMI (kg/m²)
A组	31	41.98±10.23	17(54.84)	14(45.16)	20.49±1.53
B组	51	41.98±7.13	25(49.02)	26(50.98)	20.58±1.55
C组	79	42.06±9.93	37(46.84)	42(53.16)	20.58±1.77
统计检验值		F=0.06	χ²=0.57		F=0.08
P值		0.941	0.752		0.913

表1

表2

参考文献 13

[1]	Phillips PP, Davies GR, Mitchison DA . Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis, 2010,10(2):69-70. doi: 10.1016/S1473-3099(09)70256-7 URL
[2]	Siddiqi K, Lambert ML, Walley J . Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis, 2003,3(5):288-296. doi: 10.1016/S1473-3099(03)00609-1 URL
[3]	Goletti D, Raja A , Syed Ahamed Kabeer B, et al. Is IP-10 an accurate marker for detecting M.tuberculosis-specific response in HIV-infected persons? PLoS One, 2010,5(9):e12577. doi: 10.1371/journal.pone.0012577 URL
[4]	中华医学会结核病学分会. 肺结核诊断和治疗指南. 中华结核和呼吸杂志, 2001,24(2):70-74.
[5]	Walrath J, Zukowski L, Krywiak A , et al. Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am J Respir Cell Mol Biol, 2005,33(1):48-55. doi: 10.1165/rcmb.2005-0060OC URL
[6]	Ruhwald M, Bjerregaard-Andersen M, Rabna P , et al. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M.tuberculosis in a whole blood based T-cell assay. BMC Res Notes, 2009,2:19. doi: 10.1186/1756-0500-2-19 URL
[7]	Chen YC, Chin CH, Liu SF , et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Dis Markers, 2011,31(2):101-110. doi: 10.1155/2011/938794 URL
[8]	Azzurri A, Sow OY, Amedei A , et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect, 2005,7(1):1-8. doi: 10.1016/j.micinf.2004.09.004 URL
[9]	Chen DY, Shen GH, Chen YM , et al. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis. Int J Tuberc Lung Dis, 2011,15(2):192-200.
[10]	Cannas A, Calvo L, Chiacchio T , et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis, 2010,10:333. doi: 10.1186/1471-2334-10-333 URL
[11]	Riou C, Perez Peixoto B, Roberts L , et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One, 2012,7(5):e36886. doi: 10.1371/journal.pone.0036886 URL
[12]	Su WL, Perng WC, Huang CH , et al. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin Vaccine Immunol, 2010,17(2):223-231. doi: 10.1128/CVI.00381-09 URL
[13]	Kabeer BS, Raja A, Raman B , et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis, 2011,11:135. doi: 10.1186/1471-2334-11-135 URL

[1]	段李明, 丁超, 刘玉钢, 韦林, 谷振宁. 电视辅助胸腔镜手术在慢性结核性脓胸治疗中的应用价值[J]. 中国防痨杂志, 2020, 42(8): 850-853.
[2]	刘琳. 35例妊娠期结核性胸膜炎患者临床诊疗结果分析[J]. 中国防痨杂志, 2020, 42(7): 731-736.
[3]	鲍锐, 刘晓阳, 任鹏, 张峰, 梁海燕, 王茹, 付玲, 甘地守. 脊柱结核并发HIV感染患者手术治疗特点分析[J]. 中国防痨杂志, 2020, 42(6): 645-648.
[4]	何敏, 蒲育, 蔡玉郭, 李邦银, 何磊, 环明苍. 23例脊柱结核并发艾滋病患者的手术疗效观察[J]. 中国防痨杂志, 2020, 42(5): 454-458.
[5]	宾松涛, 王继, 谭力, 吴澄清, 王艳春, 李明. 11例儿童气管支气管结核支气管镜诊断与介入治疗效果观察[J]. 中国防痨杂志, 2020, 42(5): 523-526.
[6]	康怡,傅满姣. 11例妊娠或产褥期重症结核病患者的临床治疗效果分析[J]. 中国防痨杂志, 2020, 42(4): 385-390.
[7]	简奕娈,吴龙章,古卓云. 18例五官非结核分枝杆菌病患者的临床特征及疗效分析[J]. 中国防痨杂志, 2020, 42(3): 255-258.
[8]	李志明,俞珊,王涛. 柴竹石膏汤对29例反复发热结核病并发其他感染患者的疗效分析[J]. 中国防痨杂志, 2020, 42(2): 121-125.
[9]	陈品儒,谭守勇. 外科手术在非结核分枝杆菌肺病治疗中的作用探讨[J]. 中国防痨杂志, 2020, 42(2): 159-163.
[10]	汤玉婷, 桑莹莹, 夏超. 中医适宜技术在结核病治疗中临床应用效果的研究进展[J]. 中国防痨杂志, 2020, 42(12): 1339-1342.
[11]	王振龙, 吴小英, 许红梅. 23例原发性免疫缺陷病接种卡介苗后发生播散性卡介菌病的临床特征及疗效分析[J]. 中国防痨杂志, 2020, 42(10): 1042-1047.
[12]	白云松, 张学军, 曹隽, 冯磊, 祁新禹, 郭东, 姚子明, 李承鑫. 一期前后路联合手术治疗儿童腰椎结核的临床疗效分析[J]. 中国防痨杂志, 2020, 42(10): 1048-1052.
[13]	张锋, 王曼知, 危松青, 张小佛, 周海依. 17例儿童泌尿系结核临床特征与疗效分析[J]. 中国防痨杂志, 2020, 42(10): 1061-1067.
[14]	赵永杰,钱南平. 16例脊柱结核并发艾滋病患者的手术治疗效果分析[J]. 中国防痨杂志, 2019, 41(8): 838-842.
[15]	任航空,段李明,张毅,胡明军. 手术治疗结核性脓胸并发静止期肝硬化患者的疗效分析[J]. 中国防痨杂志, 2019, 41(8): 843-847.